Pharming Group N.V.
No enriched coverage for $PHAR in the last 7 days.
No SEC Form 4 filings for $PHAR in the last 30 days.
See all $PHAR insider activity →Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.
Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.
European stocks rose slightly after Israel and Lebanon agreed to renew a fragile ceasefire, while oil prices fell more than 1% toward $96/bbl. STOXX 600 added 0.2% to 622.14; DAX +0.6% and CAC 40 +0.8%, but FTSE 100 -0.4% as BP and Shell dragged. Vivendi -4.6%; Remy Cointreau +11%; UMG -5.6%; CMC Markets +13%.
Recent PHAR coverage spans financial news, earnings and market movers.
Guidance reset increases downside risk to 2026 revenue and profitability, with Ruconest weakness the stated driver.
Guidance cut plus improving operating expense outlook, alongside strong Joenja growth and planned Q4 2026 leniolisib data, sets up a near-term sentiment swing.
Regulatory acceptance reduces approval uncertainty and can re-rate the probability of progress.
Regulatory acceptance and a defined PDUFA date materially de-risks the pediatric label expansion path for Joenja.
This is an investor-conference appearance with no new clinical, financial, or deal datapoints disclosed in the article.
alphai scores every news story that mentions PHAR with an AI model for sentiment and relevance, and aggregates insider trades from Pharming Group N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.
4 min readPharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.
7 min readEuropean stocks rose slightly after Israel and Lebanon agreed to renew a fragile ceasefire, while oil prices fell more than 1% toward $96/bbl. STOXX 600 added 0.2% to 622.14; DAX +0.6% and CAC 40 +0.8%, but FTSE 100 -0.4% as BP and Shell dragged. Vivendi -4.6%; Remy Cointreau +11%; UMG -5.6%; CMC Markets +13%.
4 min readPharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.
4 min readPharming Group said its CEO, Fabrice Chouraqui, will take part in a fireside chat Q&A at the 2026 Jefferies Global Healthcare Conference in New York on June 4 at 11:05am EDT/17:05 CEST. The company will provide a live webcast and replay on its website. The event runs June 3-4, 2026.
1 min readPharming Group said shareholders approved all proposals at its May 28, 2026 AGM. KPMG Accountants N.V. was appointed independent external auditor for 2026–2028. The meeting also approved changes to the Board remuneration policy for non-executive directors and renewed authorizations to issue and repurchase shares, according to the company.
2 min readPharming Group reported its first quarter 2026 financial results, with total revenues decreasing by 8% to US$72.4 million compared to Q1 2025. While RUCONEST® revenue declined due to anticipated inventory drawdowns and market exits, Joenja® revenue grew by 34% to US$14.1 million, driven by strong patient uptake. The company reaffirmed its 2026 total revenue guidance and announced progress on Joenja®'s pediatric label expansion in the U.S. and launches in Japan and Europe.
3 min readPharming Group N.V. is presenting new data at the 2026 Annual Meeting of the Clinical Immunology Society, focusing on its drug leniolisib. Presentations will cover interim outcomes for leniolisib in pediatric APDS patients, clinical experience in CVID and CVID-like disorders, and insights into other primary immunodeficiencies. These presentations highlight the ongoing clinical trials and the company's commitment to advancing understanding and treatment of rare immunological conditions.
3 min readThis article analyzes Pharming Group N.v. (NASDAQ: PHAR), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional risk-reward setup targeting a 12.5% gain versus 0.3% risk, along with positive prevailing sentiment. The piece also details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for various risk profiles and holding periods.
5 min readPharming Group NV's stock has reached a 52-week high of $17.89, currently trading at $17.94, reflecting strong investor confidence and a "GREAT" Financial Health Score. This surge is supported by a 90.24% price return over the past year, an 89.9% gross profit margin, and 26.78% revenue growth. The company also recently announced FDA approval for its drug leniolisib for children aged 4 to 11 with APDS, further expanding its market presence.
3 min read
